story of the week
Efficacy and Safety of the Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing–Remitting MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
JAMA Neurol 2023 Jan 23;[EPub Ahead of Print], B Hemmer, H Wiendl, K Roth, H Wessels, J Höfler, C Hornuss, B Liedert, K SelmajFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.